Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 011.05
3 605.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd
Total Liabilities & Equity
Dr. Lal PathLabs Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Total Liabilities & Equity
₹26B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Total Liabilities & Equity
₹5B
|
CAGR 3-Years
47%
|
CAGR 5-Years
38%
|
CAGR 10-Years
22%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Total Liabilities & Equity
₹6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Total Liabilities & Equity
₹9.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Total Liabilities & Equity
₹11.7B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Total Liabilities & Equity
₹16.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Dr. Lal PathLabs Ltd
Glance View
Dr. Lal PathLabs Ltd. traces its origins back to 1949 when Dr. S.K. Lal, a committed professional with a vision for transforming patient care in India, laid its foundation. With a single laboratory in Delhi, the firm embarked on a journey to make diagnostic services accessible, accurate, and affordable for millions. Over the years, the company's dedication to eking out a niche in the healthcare sector was epitomized by its expansive network that bridges urban and rural India. As of today, it boasts a robust footprint with thousands of patient service centers and diagnostic facilities, enabling them to deliver high-quality pathology services across the length and breadth of the country. This network is instrumental in addressing the diagnostic needs of individuals, bringing specialized tests and healthcare packages within arm's reach of the populace, thus weaving healthcare into the fabric of everyday life. Financially, Dr. Lal PathLabs Ltd. thrives on a well-oiled operational model that deftly balances reach, scalability, and innovation. The company's revenue streams are predominantly anchored in routine and specialized pathology tests, ranging from basic blood tests to complex genetic analyses. By deploying state-of-the-art technology and adhering to high standards of quality control, the firm ensures precision, which instills trust and sustains its business growth. Additionally, strategic collaborations with hospitals, corporate health programs, and wellness initiatives further bolster its financial health. This integrative approach, coupled with a commitment to swallowing costs through operational efficiencies, allows Dr. Lal PathLabs to maintain competitive pricing strategies, thus ensuring sustainable profitability while continuing to innovate in the face of an ever-evolving healthcare landscape.
See Also
What is Dr. Lal PathLabs Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
26B
INR
Based on the financial report for Sep 30, 2024, Dr. Lal PathLabs Ltd's Total Liabilities & Equity amounts to 26B INR.
What is Dr. Lal PathLabs Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
14%
Over the last year, the Total Liabilities & Equity growth was 6%. The average annual Total Liabilities & Equity growth rates for Dr. Lal PathLabs Ltd have been 12% over the past three years , 14% over the past five years .
You don't have any saved screeners yet